Results 11 to 20 of about 3,301,468 (320)

Therapeutic options for carbapenem-resistant Enterobacteriaceae infections. [PDF]

Virulence, 2017
In recent years, carbapenem resistance among Enterobacteriaceae has dramatically increased and represents an important threat to global health. The optimal therapeutic management of carbapenem-resistant Enterobacteriaceae (CRE) infections has not been ...
Trecarichi EM, Tumbarello M.
europepmc   +5 more sources

Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections. [PDF]

Open Forum Infect Dis, 2015
This article provides a comprehensive review of currently available treatment options for infections due to carbapenem-resistant enterobacteriaceae (CRE).
Morrill HJ, Pogue JM, Kaye KS, LaPlante KL.   +3 more
europepmc   +7 more sources

Carbapenem-Resistant Enterobacteriaceae Infections in Children. [PDF]

Curr Infect Dis Rep, 2016
Carbapenem-resistant Enterobacteriaceae (CRE) are an emerging global public health threat. Infections due to CRE are associated with significant morbidity and mortality. Few therapeutic options are available for treatment of these infections, and optimal antibiotic treatment regimens are unclear.
Chiotos K, Han JH, Tamma PD.
europepmc   +6 more sources

Estimating the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in the United States Using Antibiotic Prescription Data. [PDF]

Open Forum Infect Dis, 2019
Background Polymyxins (colistin, polymyxin B) have been first-line antibiotics against carbapenem-resistant Enterobacteriaceae (CRE) infections. New anti-CRE antibiotics (ceftazidime-avibactam, meropenem-vaborbactam, plazomicin) improve outcomes in CRE ...
Clancy CJ, Potoski BA, Buehrle D, Nguyen MH.   +3 more
europepmc   +2 more sources

Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial. [PDF]

Infect Dis Ther, 2018
IntroductionTreatment options for carbapenem-resistant Enterobacteriaceae (CRE) infections are limited and CRE infections remain associated with high clinical failure and mortality rates, particularly in vulnerable patient populations.
Wunderink RG, Giamarellos-Bourboulis EJ, Rahav G, Mathers AJ, Bassetti M, Vazquez J, Cornely OA, Solomkin J, Bhowmick T, Bishara J, Daikos GL, Felton T, Furst MJL, Kwak EJ, Menichetti F, Oren I, Alexander EL, Griffith D, Lomovskaya O, Loutit J, Zhang S, Dudley MN, Kaye KS.   +22 more
europepmc   +2 more sources

Community Origins and Regional Differences Highlight Risk of Plasmid-mediated Fluoroquinolone Resistant Enterobacteriaceae Infections in Children. [PDF]

Pediatr Infect Dis J, 2019
Background: Fluoroquinolones (FQs) are uncommonly prescribed in children, yet pediatric multidrug-resistant (MDR)-Enterobacteriaceae (Ent) infections often reveal FQ resistance (FQR).
Logan LK, Medernach RL, Rispens JR, Marshall SH, Hujer AM, Domitrovic TN, Rudin SD, Zheng X, Qureshi NK, Konda S, Hayden MK, Weinstein RA, Bonomo RA.   +12 more
europepmc   +2 more sources

A Multi-Centered Case-Case-Control Study of Factors Associated With Klebsiella pneumoniae Carbapenemase-Producing Enterobacteriaceae Infections in Children and Young Adults. [PDF]

Pediatr Infect Dis J, 2019
Background: Klebsiella pneumoniae carbapenemase (KPC)–producing Enterobacteriaceae (KPC-CRE) are multidrug-resistant organisms causing morbidity and mortality worldwide.
Logan LK, Nguyen DC, Scaggs Huang FA, Qureshi NK, Charnot-Katsikas A, Bartlett AH, Zheng X, Hujer AM, Domitrovic TN, Marshall SH, Bonomo RA, Weinstein RA.   +11 more
europepmc   +2 more sources

Enterobacteriaceae infections in Saudi Arabia: a regression analysis [PDF]

Electronic Physician, 2019
Background: Carbapenem-resistant Enterobacteriaceae (CRE) are multidrug-resistant microorganisms. Infections caused by these microorganisms have limited treatment options, frequently leading to high mortality rates.
Reham Kaki
doaj   +2 more sources

Efficacy and Safety of Meropenem-Vaborbactam Versus Best Available Therapy for the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Patients Without Prior Antimicrobial Failure: A Post Hoc Analysis. [PDF]

Adv Ther, 2019
IntroductionInfections due to Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae are associated with increased morbidity and high mortality.
Bassetti M, Giacobbe DR, Patel N, Tillotson G, Massey J.   +4 more
europepmc   +2 more sources

Factors associated to prevalence and treatment of carbapenem-resistant Enterobacteriaceae infections: a seven years retrospective study in three tertiary care hospitals. [PDF]

Ann Clin Microbiol Antimicrob, 2018
The increasing incidence of carbapenem-resistant Enterobacteriaceae (CRE), has resulted in a difficult problem in the current clinical anti-infective treatment. We performed a retrospective analysis of prevalence and treatment for CRE infections patients.
Pang F, Jia XQ, Zhao QG, Zhang Y.
europepmc   +2 more sources